New Phase III Trial Testing Lupuzor™ for Lupus

The Phase III clinical trial Lupuzor™ for lupus are now open in the U.S.  and patient recruitment has begun. Patients will randomly receive placebo or the investigational drug IPP-201101 (Lupuzor) every four weeks for 48 weeks plus standard-of-care treatment. Two hundred patients will be included in this trial, spread across 45 centers (10 in the US and 35 in Europe).Recruitment should be completed by mid-2016 and the final results are anticipated at the end of 2017. LRI Board member, Dr. Daniel Wallace, of the world renowned Cedars-Sinai Medical Center, Los Angeles, is a principal investigator for the study. 

Click here to learn more about the trial.